SCIENION AG and Procognia Ltd. today announced that the Israel based leading Glycobiology and glycoanalysis company, is producing its new generation of the GlycoScopeTM, the Multi Pad product with SCIENION’s sciFLEXARRAYER technology.
Dortmund and Berlin, Germany, July 2, 2012: Many new drugs currently entering the market are biological drugs, and most of them include glycoproteins. Understanding and analyzing the glycosylation structure of these glycoproteins during development and manufacturing is crucial for the successful functioning of the drug in the human body, as they may affect the drug’s activity, immunogenicity and pharmacokinetics.
Procognia’s GlycoScopeTM platform is designed specifically for pharmaceutical companies and research labs. It focuses on the identification of glycosylation structure of glycoproteins during the research, development, and production phases of biological drugs, and can also be used for other applications such as stem cell research, vaccine development, and more. The microarray technology platform based on lectins as capture molecules enables the analysis of dozens of samples in parallel, in a simple, rapid test, with patented automatic data analysis software for accurate, same day results.
Dr. Holger Eickhoff, CEO of SCIENION AG, states: “We are very happy to announce Procognia using our sciFLEXARRAYER technology. Based in Israel, a country with a striking innovative power in the biotech and life science sector, Procognia with its focus on glycobiology is at the forefront of technical development in the lectin microarray space. In order to understand glycoproteins and glycosylation pattern alterations associated with diseases on one hand and the effect of the various process parameters on the product glycosylation, the need for effective and precise HTP glycoanalytical tools such as Procognia’s unique lectin array platform is essential.“
Dr. Ilana Belzer, Vice President of Research and Development and Operations of Procognia Ltd. states: “We see a rapidly growing market for our GlycoScopeTM integrated platform for the analysis of recombinant monoclonal antibodies and complex biopharmaceutical glycoproteins. Procognia’s technology has been launched already in a number of leading biopharmaceutical companies. When preparing the launch of our upgraded glycoanalysis product, the Multi Pad GlycoScopeTM with broader capabilities compared to the original Single Pad GlycoScopeTM, we have been looking for a reliable dispensing device for the automated high throughput production of our arrays. After testing various technologies we decided for the best: SCIENION´s sciFLEXARRAYER. This choice was based on the precise array spotting, reproducible results and the scalability capacity of the technology to meet any potential future production demands.”
SCIENION AG and its US subsidiary SCIENION US, Inc. provide systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been consequently expanded over one decade. SCIENION provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by its versatility, precision and robustness. The company is a renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various carriers.
The company operates from two sites in Germany, Dortmund and Berlin, and has a subsidiary in Princeton, New Jersey, USA.
Procognia (Israel) Ltd. is a leading biotechnology company in the fields of Glycobiology and Glycoanalysis, with an exclusive range of proprietary technologies and applications covering four key platforms: analytics, diagnostics, therapeutic antibodies and stem cells. As a publicly traded company on the Tel Aviv Stock Exchange (TASE: PRCG), Procognia established itself as a dominant player in glycomics with the development of an innovative high throughput lectin array based glycoanalysis platform technology, the GlycoScopeTM.
Based on its expertise, the company is currently focusing on the development of breakthrough in-vitro and in-vivo cancer diagnostics, targeted cancer therapy technologies and stem cell applications.
Contact SCIENION AG
Phone +49 (0)30 – 6392 1700
Fax: +49 (0)30 – 6392 1701
Contact Procognia Ltd.
Dr. Ilana Belzer
3 Habosem Street,
Phone: +972 886 34300